Cardiovascular risk in juvenile idiopathic arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1163-1171

  Coulson, Elizabeth J ^a   Ng, Wan Fai ^a,b   Goff, Iain ^a   Foster, Helen E ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Comorbidity; Coronary artery disease; Dyslipidaemia; Hyperlipidaemia; Hypertension; Juvenile idiopathic arthritis; Outcomes; Smoking

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; STEROID; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISABILITY; DISEASE CONTROL; DISEASE SEVERITY; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; MORBIDITY; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; STEROID THERAPY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK FACTORS; COMORBIDITY; CORONARY ARTERY DISEASE; DYSLIPIDAEMIA; HYPERLIPIDAEMIA; HYPERTENSION; JUVENILE IDIOPATHIC ARTHRITIS; OUTCOMES; SMOKING;

ADULT; ARTHRITIS, JUVENILE; CARDIOVASCULAR DISEASES; CHILD; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 84879802145     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket106     Document Type: Review

References (94)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975-80.
3. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
5. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
6. Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92.
7. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
8. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-31.
9. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
10. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology 2000; 39:198-204.
11. Brady SR, De Courten B, Reid CM, et al. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 2009;36:34-40.
12. Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012;41:535-44.
13. Solomon DH, Love TJ, Canning C, et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010;69:2114-7.
14. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007;66:1316-21.
15. Ekdahl C, Broman G. Muscle strength, endurance, and aerobic capacity in rheumatoid arthritis: a comparative study with healthy subjects. Ann Rheum Dis 1992;51: 35-40.
16. Law RJ, Breslin A, Oliver EJ, et al. Perceptions of the effects of exercise on joint health in rheumatoid arthritis patients. Rheumatology 2010;49:2444-51.
17. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
18. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54:1378-89.
19. Del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
20. Sattar N, McCarey DW, Capell H, et al. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
21. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52: 2293-9.
22. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
23. Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007;9: R116.
24. Pietri P, Vyssoulis G, Vlachopoulos C, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006;24: 2231-8.
25. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
26. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905-12.
27. Van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
28. Hinks A, Barton A, John S, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005; 52:1694-9.
29. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002;41:1183-9.
30. Järvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002;22: 1323-8.
31. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
32. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121(10 Suppl 1):S21-31.
33. Cummins C, Connock M, Fry-Smith A, et al. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6:1-43.
34. Ohlsson V, Baildam E, Foster H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology 2008;47:555-6.
35. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
36. De Benedetti F, Vivarelli M, Pignatti P, et al. Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis. J Rheumatol 2000;27:2246-50.
37. Kozera L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis-the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology 2011;50: 1944-54.
38. Bharti BB, Kumar S, Kapoor A, et al. Assessment of left ventricular systolic and diastolic function in juvenile rheumatoid arthritis. J Postgrad Med 2004;50:262-7.
39. Oguz D, Ocal B, Ertan U, et al. Left ventricular diastolic functions in juvenile rheumatoid arthritis. Pediatr Cardiol 2000;21:374-7.
40. Alkady EA, Helmy HA, Mohamed-Hussein AA. Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis. Rheumatol Int 2012;32: 39-46.
41. Breda L, Di Marzio D, Giannini C, et al. Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 2013;102: 63-71.
42. van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011;40: 389-97.
43. Gonzalez-Juanatey C, Llorca J, Martin J, et al. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366-71.
44. Vlahos AP, Theocharis P, Bechlioulis A, et al. Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res 2011;63:1736-44.
45. Pietrewicz E, Urban M. [Early atherosclerosis changes in children with juvenile idiopathic arthritis]. Pol Merkur Lekarski 2007;22:211-4.
46. Argyropoulou MI, Kiortsis DN, Daskas N, et al. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin Exp Rheumatol 2003;21:794-7.
47. Nash AA, Britto MT, Lovell DJ, et al. Substance use among adolescents with juvenile rheumatoid arthritis. Arthritis Care Res 1998;11:391-6.
48. Khuder SA, Price JH, Jordan T, et al. Cigarette smoking among adolescents in Northwest Ohio: correlates of prevalence and age at onset. Int J Environ Res Public Health 2008;5:278-89.
49. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7.
50. Ilowite NT, Samuel P, Beseler L, et al. Dyslipoproteinemia in juvenile rheumatoid arthritis. J Pediatr 1989;114:823-6.
51. Tselepis AD, Elisaf M, Besis S, et al. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum 1999;42:373-83.
52. Gonçalves M, D'Almeida V, Guerra-Shinohara EM, et al. Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis. Pediatr Rheumatol Online J 2007;5:2.
53. Bakkaloglu A, Kirel B, Ozen S, et al. Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol 1996;15:341-5.
54. Marangoni RG, Hayata AL, Borba EF, et al. Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics (Sao Paulo) 2011;66: 1549-52.
55. Dursunoǧlu D, Evrengül H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005;25:241-5.
56. Borba EF, Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001;28: 780-5.
57. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987;63:167-72.
58. Daïen CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012;71:862-8.
59. Pelajo CF, Lopez-Benitez JM, Miller LC. Obesity and disease activity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012;10:3.
60. Henderson CJ, Lovell DJ, Specker BL, et al. Physical activity in children with juvenile rheumatoid arthritis: quantification and evaluation. Arthritis Care Res 1995;8:114-9.
61. Lelieveld OT, Armbrust W, van Leeuwen MA, et al. Physical activity in adolescents with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1379-84.
62. Derdemezis CS, Voulgari PV, Drosos AA, et al. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship. Clin Exp Rheumatol 29: 712-27.
63. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol 2009;28:439-44.
64. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008;58:2268-74.
65. Cleary AG, Lancaster GA, Annan F, et al. Nutritional impairment in juvenile idiopathic arthritis. Rheumatology 2004;43:1569-73.
66. Haugen MA, Lien G, Flatoø B, et al. Minor impact of juvenile arthritis on nutritional status in young adult patients. Arthritis Rheum 2002;47:623-9.
67. Caetano MC, Sarni RO, Terreri MT, et al. Excess of adiposity in female children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol 2012;31:967-71.
68. Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12.
69. Hinks A, Martin P, Flynn E, et al. Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:2169-72.
70. Macera CA, Hootman JM, Sniezek JE. Major public health benefits of physical activity. Arthritis Rheum 2003;49: 122-8.
71. U.S. Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996. Available from: http://www.cdc.gov/nccdphp/sgr/pdf/sgrfull.pdf (8 March 2013, date last accessed).
72. Strong WB, Malina RM, Blimkie CJ, et al. Evidence based physical activity for school-age youth. J Pediatr 2005;146: 732-7.
73. Takken T, van der Net J, Kuis W, et al. Physical activity and health related physical fitness in children with juvenile idiopathic arthritis. Ann Rheum Dis 2003;62:885-9.
74. Takken T, Hemel A, van der Net J, et al. Aerobic fitness in children with juvenile idiopathic arthritis: a systematic review. J Rheumatol 2002;29:2643-7.
75. Takken T, van Brussel M, Engelbert RH, et al. Exercise therapy in juvenile idiopathic arthritis: a Cochrane Review. Eur J Phys Rehabil Med 2008;44:287-97.
76. Krebs D, Herzog W, McGibbon CA, et al. Work Group recommendations: 2002 Exercise and Physical Activity Conference, St Louis, Missouri. Arthritis Rheum 2003;49: 261-2.
77. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
78. Rantapää-Dahlqvist S, Boman K, Tarkowski A, et al. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin Mrheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis 2007;66:121-3.
79. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7: R634-43.
80. Chen C-Y. Comparison of soluble adhesion molecules in juvenile idiopathic arthritis between the active and remission stages. Ann Rheum Dis 2002;61:167-70.
81. Bloom BJ, Nelson SM, Eisenberg D, et al. Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis. J Rheumatol 2005;32:366-72.
82. Hull RG. Guidelines for management of childhood arthritis. Rheumatology 2001;40:1309-12.
83. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
84. Ardoin SP, Sundy JS. Update on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 2006;18: 221-6.
85. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 2008;47:72-5.
86. Davis JM III, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;56:820-30.
87. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
88. Simon D, Prieur A-M, Quartier P, et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007;92:2567-73.
89. Bechtold S, Ripperger P, Hafner R, et al. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 2003;143: 512-9.
90. Bismuth E, Chevenne D, Czernichow P, et al. Moderate deterioration in glucose tolerance during high-dose growth hormone therapy in glucocorticoid-treated patients with juvenile idiopathic arthritis. Horm Res Paediatr 2010;73:465-72.
91. Simon D, Prieur AM, Quartier P, et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007;92:2567-73.
92. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;46:1111-5.
93. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32: 1213-8.
94. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.